DIGN First North Stockholm
Read more about Dignitana's share at Nasdaq OMX FIRST NORTH
Slide background
Slide background

About Dignitana

Dignitana develops a patented scalp cooling system, DigniCap®, that reduces chemotherapy-induced hair loss. Dignitana's patented DigniCap® system has demonstrated excellent scientific results in clinical studies. More than eight out of ten treated patients were able to retain enough of their hair to eliminate the need for a wig.

About DigniCap®

DigniCap® provides a reliable method of continuous scalp cooling with high efficacy and an acceptable level of patient comfort. The system consists of a form-fitting silicone cap connected to a cooling and control unit. An elastic, insulating outer cap made of neoprene is used to ensure the best fit and treatment temperature. Please visit our new website for more product information www.dignicap.com.

Investor relations

Dignitana is a Swedish medical technology company listed on the NASDAQ OMX First North stock exchange. The company is currently focusing on a widespread market launch of the DigniCap® system – a product that counteracts chemotherapy-related hair loss in cancer patients and significantly contributes to improving patient well being and quality of life.

Latest news

FDA has converted Dignitana´s PMA submission into a de novo regulatory 510(k) pathway

FDA has converted Dignitana´s PMA submission into...

Keeping Your Hair in Chemo (The New York Times)

Dr. Rugo said the DigniCap may soon become the fir...

Dignitana AB Collaborates with Target Health Inc. to Conduct Pivotal Study Using Proprietary Clinical Trial Software

Dignitana AB Collaborates with Target Health Inc. ...

New Address

We have moved. Our new address is
Traktorgränden 3
SE-226 60 Lund.

Latest Media Placement: ABC 7